# Survey: Majority of Physicians Have Industry Ties

Physicians in

group practice

were three times

as likely to take

gifts and nearly

likely to receive

four times as

payments for

professional

services.

BY MARY ELLEN SCHNEIDER

New York Bureau

Tearly all physicians have ties to the pharmaceutical or device industries ranging from accepting drug samples to serving on a speakers' bureau, according to a survey of physicians across six specialties.

The study found that 94% of physicians surveyed reported some type of relationship with industry. The most frequently cited interaction (83%) was receiving food in the workplace. A majority of physicians surveyed (78%) also reported accepting drug samples.

Fewer physicians, about 35%, reported accepting reimbursement for admission to continuing medical education meetings or other meeting-related expenses, and 28% said they received payments from industry for professional services such as consulting, speaking, serving on an advisory board, or enrolling patients in clinical trials (N. Engl. J. Med. 2007;356;1742-50).

Physicians contacted by this news organization said that while the study raises important issues, it is not a cause for alarm since many of the industry interactions outlined in the study are essential and appropriate.

Eric G. Campbell, Ph.D., of the Institute for Health Policy at Massachusetts Gen-

eral Hospital–Partners Health Care System in Boston, and his colleagues surveyed 3,167 physicians working in anesthesiology, cardiology, family practice, general surgery, internal medicine, and pediatrics.

Of those surveyed, 1,662 completed the

questionnaire for an overall response rate of about 52%. The study was supported by a grant from the Institute on Medicine as a Profession.

The type and extent of reported interaction with representatives of the pharmaceutical and device industries varied by specialty, the researchers found. For example, cardiologists were more than twice as likely as family physicians to receive payments for professional

services, such as consulting or work on clinical trials.

Family physicians held the most meetings with industry representatives, on average about 16 meetings per month, according to the study.

Practice setting also played a role in the interaction. Physicians in group practice were six times more likely to receive drug samples than were those working in hos-

pitals, clinics, or staff-model health maintenance organizations. Physicians in group practice were also three times as likely to receive gifts and nearly four times as likely to receive payments for professional services.

The study did not assess the appropri-

ateness of the relationships with industry; however, the researchers concluded that the variations in relationships by specialty may indicate a need for guidelines that are specific to specialties and practice settings.

In an interview, Dr. James King, president-elect of the American Academy of Family Physicians said, "I don't think it's a major cause for concern."

Dr. King said he was not surprised by the survey find-

ings, especially since it is a common practice for physicians to accept drug samples in an effort to save their patients money. Most practices are likely operating within the guidelines set out by the American Medical Association, he said. The AMA guidelines recommend that gifts should primarily have a benefit to patients and should not be of substantial value. For example, modest meals and textbooks are ac-

ceptable under the AMA guidelines, but cash payments should not be accepted.

The relationship with industry should continue to be watched and addressed, said Dr. King, and he recommended that physicians review their own ethical guidelines from time to time and refuse to accept any gift that would inappropriately influence their prescribing habits.

The main responsibility of physicians who do have relationships with industry is to ensure that patients' interests always come first and to disclose any financial conflicts, Dr. Jack Lewin, CEO of the American College of Cardiology, said in an interview.

ACC has a policy requiring disclosure of industry relationships for anyone involved in the group's activities, he said. "We really do have a firewall."

However, many of the relationships between cardiologists and industry are necessary and appropriate, he said, since industry is the main source of research on new treatments.

But more can be done to reduce concerns about potential conflict of interest, Dr. Lewin said. For example, an increase in the number of publicly funded independent reviews of drugs and devices and increases in federal research funding would help to clarify some of the gray areas of cardiovascular care, he said.

## PRODUCTS

#### **Enjuvia for Vaginal Dryness**

Enjuvia (synthetic conjugated estrogens, B) is approved for the treatment of moderate to severe vaginal dryness and pain with intercourse, and symptoms of vulvar and vaginal atrophy associated with menopause. Enjuvia is approved in a new tablet strength, 0.9 mg. For more information, contact Barr Pharmaceuticals Inc. by visiting www.barrpharmaceuticals.com.

#### T-Shirts Available for Wound Care

SilverSeal X-Shirts are available for the management of wounds and burns on the upper torso and upper arms. These medical-grade T-shirts are made of 90% cotton and 10% X-Static silver fiber. The sustained release of silver cations provides the skin with an antimicrobial barrier. For more information, contact Noble Biomaterials Inc. by calling 877-978-2842.

# Wipes Now Kill More Microorganisms

Super Sani-Cloth Germicidal Disposable Wipes now kill rotavirus, human coronavirus, ESBL-producing *E. coli* and *Burkholderia cepacia*, in addition to more than a dozen other microorganisms. For more information or to purchase wipes, contact Professional Disposables International at www.pdipdi.com.

## **New Twinrix Dosing Schedule**

The Food and Drug Administration has approved an accelerated dosing schedule for Twinrix (Hepatitis A Vaccine [Inactivated] and Hepatitis B [Recombinant] Vaccine). Three doses can be administered at 0, 7, 21-30 days, followed by a booster at 12 months, according to GlaxoSmithKline. Twinrix was approved for adults in 2001, on a 0-, 1-, and 6-month schedule. For more information, visit www.gskvaccines.com.

# FYI

#### Skin Care Web Site Launched

A new Web site offers information on the treatment and management of aging skin. The site, www.agingwithbeauty.com, gives information on techniques such as microdermabrasion and chemical peels, and offers tips on slowing the aging process. It is sponsored by Sanofi-Aventis.

#### **Quality Reporting Questions Answered**

More than 50 frequently asked questions about the Physician Quality Reporting Initiative are available on the Web site of the Centers for Medicare and Medicaid Services. Visit www.cms.hhs.gov/PQRI

and scroll down to the "Related Links Inside CMS" section. Click on the "All PQRI FAQs" link to access the list.

#### **Overview of Covering the Uninsured**

The Alliance for Health Reform is offering an overview of how health coverage is obtained. "Health Care Coverage in America: Understanding the Issues and Proposed Solutions," includes topics such as who is uninsured, approaches to covering the uninsured, and coverage proposals. Go to www.allhealth.org/publications/uninsured/health\_care\_coverage\_in\_america\_2007\_54.pdf to download.

#### Web-Based EMR Service Offered

A new Web site is offering an Internetbased electronic medical records system that needs no special software purchase. Subscription plans vary and are available at an annual or monthly rate. For more information, visit www.docpatient.com.

#### **Laser and Pulsed Light System**

The StarLux 500 platform is available for nonablative skin resurfacing, soft tissue coagulation, and permanent hair reduction, as well as the treatment of leg veins, pigmented lesions, vascular lesions, and acne.

Different application-specific handpieces can be attached to the compact base unit. For more information, contact Palomar Medical Technologies by visiting www. palomarmedical.com.

### **Chlorascrub Swabs Available for Kits**

Chlorascrub Swabs, formulated with 3.15% chlorhexidine gluconate and 70% isopropyl alcohol, are available for inclusion in first aid kits, and for kit manufacturers. They are manufactured by PDI, the health care division of Nice-Pak Products Inc. For more information, visit www.pdipdi.com.

# INDEX OF ADVERTISERS

Humira	23-28
Allergan, Inc.	
Botox	30-32
Juvederm	5.5
Astellas Pharma US, Inc.	
Amevive	36a-360
Barrier Therapeutics, Inc.	
Xolegel	20a-20b
Vusion	68a-68l
Bayer HealthCare Pharmaceuticals, Inc	
Yaz	41-42
CollaGenex Pharmaceuticals, Inc.	
Oracea	66-68
CORIA Laboratories, Ltd.	
Salex Shampoo	7-8
Cloderm	77-78
CynoSure	
Cynergy	39
DUSA Pharmaceuticals, Inc.	
ClindaReach	52a-52b, 53
Ferndale Laboratories	
Locoid Lipoderm	14-15, 43-44
Galderma Laboratories, L.P.	
MetroGel	5-6
Differin	11-12
Clobex	56a-56l

DVERTISERS		
Graceway Pharmaceuticals, LLC Atopiclair	83	
Medicis Pharmaceutical Corporation		
Solodyn Ziana	16a-16b 32a-32b, 33	
OrthoNeutrogena Retin-A Micro	3-4	
PCA Advanced Skin Care Systems Anti-redness serum	75	
PharmaDerm		
Oxistat Cutivate	35-36 71-72	
SkinMedica, Inc. Desonate	59-60	
Spear Dermatology Products, Inc. Tretinoin	73-74	
Stiefel Laboratories, Inc.		
Corporate	14	
Revale Sarna Original	18-19 29	
Sarna Sensitive	47	
MimyX	51-52	
ZNP Bar	63	
Rosac Wash	81	
Duac	87-88	
Travel Tech Mohs Services, Inc.		
Corporate	10	
Wyeth Pharmaceuticals Inc.	44a-44d. 45	